{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Vaxart, Inc.
Is Vaxart, Inc. overvalued or undervalued?
As of August 3, 2023, Vaxart, Inc. is rated as risky and overvalued, with key financial metrics indicating poor performance compared to peers and a year-to-date return of -41.85%, significantly underperforming the S&P 500's 12.22%.
Is Vaxart, Inc. overvalued or undervalued?
As of August 3, 2023, Vaxart, Inc. is considered overvalued and categorized as "risky" due to troubling financial metrics, including a Price to Book Value of 2.03, an EV to Sales ratio of 1.22, a ROCE of -535.64%, and poor stock performance with a year-to-date return of -15.36%, significantly underperforming the S&P 500.
Is Vaxart, Inc. technically bullish or bearish?
As of June 6, 2025, Vaxart, Inc. is in a mildly bearish trend, primarily due to daily moving averages indicating bearish conditions, while longer-term indicators show mixed signals.
Who are in the management team of Vaxart, Inc.?
As of March 2022, the management team of Vaxart, Inc. includes Dr. Wouter Latour (Chairman), Mr. Andrei Floroiu (CEO), Mr. Robert Yedid (Lead Independent Director), and several other directors. They oversee the company's strategic direction and operations.
What does Vaxart, Inc. do?
Vaxart, Inc. is a micro-cap biotechnology company focused on developing direct-acting antivirals for infections. As of March 2025, it reported net sales of $21 million and a net loss of $16 million, with a market cap of $136 million.
How big is Vaxart, Inc.?
As of Jun 18, Vaxart, Inc. has a market capitalization of 136.00 million and reported net sales of 47.40 million with a net profit of -58.12 million over the latest four quarters. Shareholder's funds are 58.92 million, and total assets amount to 166.39 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
